Autolus Therapeutics
AUTL
46 hedge funds and large institutions have $142M invested in Autolus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 9 closing their positions.
3.72% less ownership
Funds ownership: 27.43% → 23.71% (-3.7%)
8% less funds holding
Funds holding: 50 → 46 (-4)
38% less capital invested
Capital invested by funds: $230M → $142M (-$88M)
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.82M |
| 2 |
JP Morgan Chase
New York
|
+$549K |
| 3 |
Two Sigma Investments
New York
|
+$481K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$419K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$363K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.39M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.21M |
| 3 |
EP
Eversept Partners
New York
|
-$4.14M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$3.19M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.67M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Tudor Investment Corp
Stamford,
Connecticut
| – | -$425K | -26,513 | Closed |
|
52
Marshall Wace
London,
United Kingdom
| – | -$220K | -13,672 | Closed |
|
53
Jane Street
New York
| – | -$218K | -13,590 | Closed |
|
|
BG
54
Bollard Group
Boston,
Massachusetts
| – | -$53K | -3,276 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$44 | +3 | New |
|
AUTL Hedge Fund Activity: Q3 2020 in Review
46 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2020, worth a combined $142M — down 38% from $230M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AUTL and 5 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 11 added.
The largest buyer was Granahan Investment Management, adding an estimated $3.82M. The largest seller was Millennium Management, cutting an estimated $8.39M.
- 46 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2020, down from 50 in Q2 2020.
- Funds reported $142M of Autolus Therapeutics stock for Q3 2020, down 38% quarter-over-quarter.
- 5 funds opened new Autolus Therapeutics positions in Q3 2020 and 9 closed out, a net change of -4 holders.
- The largest Autolus Therapeutics buyer in Q3 2020 was Granahan Investment Management, an estimated $3.82M added.
- The largest Autolus Therapeutics seller in Q3 2020 was Millennium Management, an estimated $8.39M sold.
Based on aggregated 13F filings for Q3 2020.